ArticleWorld journal of surgical oncology2006
Liver metastases of neuroendocrine tumours; early reduction of tumour load to improve life expectancy.
Article in World journal of surgical oncology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 53 citations in OpenAlex.
- Trial
- Comparison study of gastrinomas between gastric and non-gastric origins.World journal of surgical oncology · 2015Trial
- The Role of High-Dose-Rate Brachytherapy (Interventional Radiotherapy) in the Reirradiation of Liver Metastases.Cancers · 2025Article
- Chemoembolization Beyond Hepatocellular Carcinoma: What Tumors Can We Treat and When?Seminars in interventional radiology · 2024Review
- Neuroendocrine Tumors: Genomics and Molecular Biomarkers with a Focus on Metastatic Disease.Cancers · 2023Review
- Mixed neuroendocrine-non-neuroendocrine carcinoma (MiNEN) in gallbladder with liver metastasis of neuroendocrine carcinoma component: a case report.Journal of surgical case reports · 2023Article
- Diagnostic Management of Gastroenteropancreatic Neuroendocrine Neoplasms: Technique Optimization and Tips and Tricks for Radiologists.Tomography (Ann Arbor, Mich.) · 2023Review
- Role of Cell Block Technology as an Adjunct to Fine Needle Aspiration in Evaluating as well as Differentiating Liver Lesions.Iranian journal of pathology · 2021Article
- Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review.Frontiers in oncology · 2020Review
- The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: the radiologist's challenge.Radiology and oncology · 2019Review
- Vitamin D and vitamin BBMJ case reports · 2019Article
- Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases.European journal of nuclear medicine and molecular imaging · 2016Article
- Ki67 score as a potential predictor in the selection of liver-directed therapies for metastatic neuroendocrine tumors: a single institutional experience.Journal of gastrointestinal oncology · 2016Article
- Expression of CD24, a Stem Cell Marker, in Pancreatic and Small Intestinal Neuroendocrine Tumors.American journal of clinical pathology · 2015Article
- MRI-guided laser ablation of neuroendocrine tumor hepatic metastases.Acta radiologica short reports · 2014Article
- Treatment of neuroendocrine tumor liver metastases.International journal of hepatology · 2012Article
- Predictors of response to radio-embolization (TheraSphere®) treatment of neuroendocrine liver metastasis.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2012Article
- Multimodal management of neuroendocrine liver metastases.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2010Review
- Multimodality treatment of unresectable hepatic metastases from pancreatic glucagonoma.Rare tumors · 2009Article
- Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases.Diagnostic and interventional radiology (Ankara, Turkey)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuroendocrine tumours frequently metastasize to the liver. Although generally slowly progressing, hepatic metastases are the major cause of carcinoid syndrome and ultimately lead to liver dysfunction, cardiac insufficiency and finally death.
methodsA literature review was performed to define the optimal treatment strategy and work-up in patients with neuroendocrine hepatic metastases. Based on this, an algorithm for the management of these patients was established.
resultsPlatelet serotonin and chromogranin A are useful biomarkers for detection and follow-up of neuroendocrine tumour. Helical computed tomography and somatostatin receptor scintigraphy are the most sensitive diagnostic modalities. Surgical debulking is an accepted approach for reducing hormonal symptoms and to establish better conditions for medical treatment, but is frequently impossible due to the extent of disease. A novel approach is the local ablation of tumour by thermal coagulation using therapies such as radiofrequency ablation (RFA) or laser induced thermotherapy (LITT). These techniques preserve normal liver tissue. There is a tendency to destroy metastases early in the course of disease, thereby postponing or eliminating the surgically untreatable stage. This can be combined with postoperative radioactive octreotide to eliminate small multiple metastases. In patients with extensive metastases who are not suitable for local destruction, systemic therapy by octreotide, 131I-MIBG treatment or targeted chemo- and radiotherapy should be attempted. A final option for selective patients is orthotopic liver transplantation.
conclusionTreatment for patients with neuroendocrine hepatic metastases must be tailored for each individual patient. When local ablative therapies are used early in the course of the disease, the occurrence of carcinoid syndrome with end stage hepatic disease can be postponed or prevented.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.